Pre-Screening Questionnaire and Your Privacy
Please be advised that by filling out the study pre-screening questionnaire below, you will be asked to provide personal information, including age, gender, and your current medical condition. One of our staff will then reach out to conduct a phone-screen to see if you qualify for one of our current studies at our office location in Oceanside, CA. Your privacy is of the utmost importance to Excell Research. Your privacy will be protected and the information you provide will only be shared with those involved with the clinical research study if it is determined that you may be eligible to participate, unless you permit us to do so or except as required by law. Your information will not be sold to outside companies, nor will it be stored or collected without your direct consent.
Many Pharmaceutical Companies and Excell Research are conducting these studies under the Food and Drug Administration (FDA) to learn more about new investigational drugs or treatments. Read our privacy policy to learn more about how your information will be kept private.
Active Studies and Additional Information
1. Sponsor: Alto Neuroscience
Protocol Number: ALTO-100-201
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ALTO-100 With an Open-Label Extension in Adults With Major Depressive Disorder
Inclusion Criteria:
- Ages: 18-64
- Have a diagnosis of moderate to severe major depressive disorder (MDD)
- Can stay on an antidepressant medication if taking one.
- Must not be pregnant or breastfeeding at time of enrollment or throughout study
- Reimbursement for time and travel up to $700
Exclusion Criteria:
- Evidence of unstable medical condition
- Diagnosed bipolar disorder, psychotic disorder, or dementia
- Current moderate or severe substance use disorder
- Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device.
2. Sponsor: DeNovo Biopharma LLC
Protocol Number: DB104-01
A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment Resistant Depression
Inclusion Criteria:
- Ages: 18-64
- Have a diagnosis of moderate to severe major depressive disorder (MDD)
- Has tried 2 or more Antidepressants of a different class in the past 5 years.
- Must not be pregnant or breastfeeding at time of enrollment or throughout study
- Reimbursement for time and travel up to $900
- Sponsor: Sunovion Pharmaceuticals
Protocol Number: SEP361-226
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder
Inclusion criteria:
- Age 18-65
- Moderate to Severe symptoms of Generalized Anxiety
- No Previous diagnosis required
- Reimbursement for time and travel up to $1,500
- Sponsor: Neurocrine Biosciences
Protocol Number: NBI-98854-ATS3019 & NBI-1065844-CIAS2023
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia
Inclusion criteria:
- Age 18-75
- Currently being treated with an anti-psychotic medication.
- Reimbursement for time and travel up to $1,200
- Sponsor: Biohaven Pharmaceuticals
Protocol Number: BHV4157-302
A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Inclusion criteria:
- Age 18-65
- Moderate to severe symptoms of OCD.
- Currently taking an SSRI medication for 8 weeks prior to the study.
- Reimbursement for time and travel up to $700.
- Sponsor: Abbvie Pharmaceuticals
Protocol Number: 3110-305-002 & M21-201
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)
Inclusion criteria:
- Age 11-17 (Excell Research Age Range)
- Have up to 4 Migraines days a month.
- No previous medications required.
- Reimbursement for time and travel up to $300.
- Sponsor: Otsuka Pharmaceuticals
Protocol Number: 20-AVP-786-306
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer’s Type
Inclusion criteria:
- Age 50-90
- Previous diagnosis of Alzheimer’s Disease and a legal caregiver required.
- Reimbursement for time and travel up to $1,000 for patient and caregiver.